Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients With Unresectable Stage III or Stage IV Cutaneous Melanoma

NCT03655756 is registered in ClinicalTrials.gov with TuHURA Biosciences, Inc. as lead sponsor.

NCT NCT03655756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03655756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients With Unresectable Stage III or Stage IV Cutaneous Melanoma
Lead sponsor
TuHURA Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2018
Completion date
November 30, 2020
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, stage iii, cutaneous melanoma, stage iv